| Volume: | 7,366,209 |
|---|---|
| Day's Low: | $22.40 |
| 52-wk Low: | $17.23 |
| Previous Close: | $22.50 |
| Dividend: | $0.31 |
| Market Cap: | 44,849,400 |
| Avg Volume: | 10,028,100 |
|---|---|
| Day's High: | $22.68 |
| 52-wk High: | $23.98 |
| Open Price: | $22.56 |
| Yield: | 5.48% |
| P/E (Forward): | 11.15 |
| 1:06 PM | 11/5/2009 | Amgen's Vectibix Misses Survival Goal,But Sales Could Benefit |
| 10:33 AM | 11/2/2009 | US Supreme Court Rejects Plavix Patent Challenge |
| 3:08 PM | 10/22/2009 | US Drug Makers 3Q Helped By Cost Cuts, Major Product Sales |
| 12:14 PM | 10/22/2009 | Teva Seeks To Sell Generic Version Of Bristol HIV Drug |
| 11:48 AM | 10/22/2009 | UPDATE: Bristol-Myers 3Q Net Down 63% On Year-Ago Gains |
| 7:46 AM | 10/22/2009 | Bristol-Myers 3Q Net Down 63% On Year-Ago Gains |
| 11:38 AM | 10/21/2009 | 2nd UPDATE: Lilly Swings To 3Q Profit From Year-Ago Charges |
| 11/5/2009 | Cramer on BloggingStocks: All I'm asking for is rigor |
| 11/3/2009 | The Lure of High-Yielding Stocks |
| 11/3/2009 | 'Hope' Trade Still Has Legs |
| 11/2/2009 | Court Rejects Drug-Patent Challenge |
| 11/2/2009 | Turnaround Letter not for faint of heart |
| 10/29/2009 | 3 Stocks for Contrarian Investors |
| 10/28/2009 | Stock sleuth exposes winners and traps |
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | 0.52 | 0.46 | 13.04 |
| EPS, GAAP | 0.48 | 1.29 | -62.79 |
| Consensus Estimate | 0.51 | 0.42 | 21.43 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | 2.02 | 1.74 | 16.09 |
| EPS, GAAP | 1.92 | 1.95 | -1.54 |
| Consensus Estimate | 1.86 | NA | NA |
| BMY | Industry Average | |
| P/E (TTM) | 11.79 | 18.40 |
| P/E (Forward) | 11.15 | -4.30 |
| PEG Ratio | 1.51 | -0.28 |
| Price/Sales | 2.13 | 2.94 |
| Beta | 0.67 | 0.65 |